Human myeloperoxidase: A potential target for molecular MR imaging in atherosclerosis

Magnetic Resonance in Medicine

Volumn 52, Issue 5, 2004, Pages 1021-1028

  Chen, John W ^a   Pham, Wellington ^a   Weissleder, Ralph ^a   Bogdanov Jr , Alexei ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; Inflammation; Magnetic resonance imaging

Indexed keywords

ENZYME ACTIVITY; LEAD COMPOUNDS; MAGNETIC RESONANCE IMAGING; PARAMAGNETISM; PATHOLOGY;

ATHEROSCLEROSIS; ELECTRON DONORS; ENZYME SOLUTIONS; HUMAN NEUTROPHIL; INFLAMMATION; MYELOPEROXIDASE; POTENTIAL SUBSTRATE; POTENTIAL TARGETS;

DISEASES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; GADOLINIUM; MYELOPEROXIDASE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PROTON; SEROTONIN;

ARTERY; ARTICLE; ATHEROSCLEROSIS; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME SUBSTRATE; EXPERIMENTAL MODEL; NEUTROPHIL; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION; POLYMERIZATION; TISSUE DISTRIBUTION;

EID: 7544221356     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.20270     Document Type: Article

References (23)

1. The World Health Report: The World Health Organization; 2003. p. 85-102.
2. Hackarm D, Anand S. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003;290(7):932-940.
3. Davies M. Stability and instability: two faces of coronary atherosclerosis: the Paul Dudley White Lecture 1995. Circulation 1996; 94:2013-2020.
4. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res 2001;89(4):305-316.
5. Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Dangas G, Moussa I, Mehran R, Lansky AJ, Kreps E, Collins M, Colombo A, Stone GW, Leon MB, Moses JW. Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. Circulation 2003;108(20):2473-2478.
6. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91(11):2844-2850.
7. Higuchi ML, Gutierrez PS, Bezerra HG, Palomino SA, Aiello VD, Silvestre JM, Libby P, Ramires JA. Comparison between adventitial and intimai inflammation of ruptured and nonruptured atherosclerotic plaques in human coronary arteries. Ar Qbras Cardiol 2002;79(1):20-24.
8. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Jr., Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003;108(15):1772-1778.
9. Libby P, Aikawa M. Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. Clin Cardiol 2003;26(1 Suppl 1):I11-14.
10. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Jr., Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003;108(14):1664-1672.
11. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002;88(4):554-567.
12. Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002;106(23):2894-2900.
13. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003;349(17):1595-1604.
14. Heinecke JW. Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Biofactors 1997;6(2):145-155.
15. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996;97(6):1535-1544.
16. Malle E, Waeg G, Schreiber R, Grone EF, Sattler W, Grone HJ. Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 2000;267(14): 4495-4503.
17. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001;276(44):41279-41287.
18. Bogdanov A, Matuszewski L, Bremer C, Petrovsky A, Weissleder R. Oligomerization of paramagnetic substrates results in signal amplification and can be useful for MR imaging of molecular targets. Mol Imaging 2002;1:1-9.
19. Heinecke JW, Li W, Daehnke HL, 3rd, Goldstein JA. Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 1993;268(6):4069-4077.
20. Klebanoff SJ, Waltersdorph AM, Rosen H. Antimicrobial activity of myeloperoxidase. Methods Enzymol 1984;105:399-403.
21. Cornish-Bowden A. Fundamentals of Enzyme Kinetics. London: Portland Press; 1995.
22. Dunford HB, Hsuanyu Y. Kinetics of oxidation of serotonin by myeloperoxidase compounds I and II. Biochem Cell Biol 1999;77(5):449-457.
23. Michon T, Chenu M, Kellershon N, Desmadril M, Gueguen J. Horse-radish peroxidase oxidation of tyrosine-containing peptides and their subsequent polymerization: a kinetic study. Biochemistry 1997;36(28): 8504-8513.